Used in research and therapeutic development targeting the complement system, particularly in conditions where CD59-mediated inhibition of membrane attack complex (MAC) formation is compromised. It serves as a reference tool for evaluating CD59 function in cell protection, autoimmune diseases, and transplant rejection. Applied in assays to block or detect CD59 activity, aiding in the study of complement-driven pathologies such as paroxysmal nocturnal hemoglobinuria (PNH), ischemia-reperfusion injury, and certain neurodegenerative disorders. Also utilized in the development and validation of biosimilars and biologics where complement regulation is a safety or efficacy concern.